Clinical Role - Specialty Pharmacy
Pharmacy Times® is a leader in providing expert insights and clinical updates to specialty pharmacists and reaches more than 200,000 pharmacy professionals in total.
For specialty pharmacies, contingency plans for COVID-19 are not as simple as moving a workforce to their remote access solutions.
Ozanimod demonstrated acceptable safety and tolerability in the phase 3 SUNBEAM and RADIANCE part B trials.
New research has examined the details surrounding the signaling molecule interleukin-2, which could lead to more targeted therapies for diseases such as cancer.
Study: Genetic Testing Recommended for Some Postmenopausal Women with Breast Cancer, No Hereditary Risk Factors
Guidelines recommend that Ashkenazi Jewish women discuss genetic testing with physicians, but other women with breast cancer are less likely to receive a recommendation of testing.
A study published in Clinical Cancer Research has shown that using standard-of-care computed tomography (CT) scans in patients with advanced non-small cell lung cancer (NSCLC) can predict tumor sensitivity to 3 systematic cancer therapies by using artificial intelligence (AI).
While remdesivir is not FDA-approved to treat the novel coronavirus, the orphan drug status would provide 7 years of exclusive marketing in the United States and tax credits on research and development costs once the drug was approved.
Research may lead to the development of new types of binding proteins for biological sugar structures, which play a significant role in cancer and infectious diseases.
Patients with a history of cancer have a greater likelihood of developing atrial fibrillation, the most common heart rhythm disorder, compared with the general population.
A discussion on the adoption of biosimilars in the US vs Europe and the potential cost savings associated.
The new study has found that the lymphedema monitoring technology, marketed by LymphaTech, can effectively detect early arm swelling associated with lymphedema in breast cancer patients.
Trastuzumab-dttb was first approved in January 2019 across all eligible indications, mainly adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer.
The FDA has issued a new guidance to sponsors and health care providers regarding certain Risk Evaluation and Mitigation Strategy-required testing during the coronavirus disease 2019 pandemic.